Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit on the host. Over the past two decades, there has been tremendous progress in elucidating probiotic mechanisms and function owing to advances in microbiome science, molecular biology, and clinical research. This review summarises the current state of probiotic research across mechanisms of action, clinical preclinical studies and future perspectives. Probiotics confer their benefits through diverse mechanisms of action, including modification of gut microbiota and fecal metabolite profiles, improvement in intestinal permeability, production of antimicrobial agents and short chain fatty acids (SCFAs), competitive inhibition against pathogenic microorganisms colonisation from attaching to epithelial cells; signalling pathways that mediate innate immunity or adaptive immune responses . The most recent evidence also shows their involvement in gut–brain interaction, regulation of metabolism homeostasis and signaling pathways involved with inflammation.

That's why clinical studies have shown that certain strains of probiotics are effective for prevention and management of gastrointestinal diseases, including antibiotic-associated diarrhea, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) as well as Clostridioides difficile infection. Apart from gastrointestinal health, probiotics have demonstrated favorable effects in metabolic disorders and allergies using microbiome-based mechanisms as well. Nevertheless, the applicability of probiotics to human medicine is extremely strain-specific and greatly influenced by dosage, duration of treatment and host factors such as genetics diet age comorbidities or microbiome composition. Despite the wealth of research publications on prostate cancer screening, variability in clinical trial design requirements and evolving regulatory guidelines have constrained broad application or enforcement across large populations as well as limited access to long-term safety data.

Recent advances in technology, such as multi-omics, metagenomics and metabolomics approaches combined with artificial intelligence (AI) machine learning tools and synthetic biology are expediting the quest for next-generation probiotics discovery towards microbiome-based personalized therapy. New formulations, such as synbiotics, postbiotics and engineered probiotics (along with mathematical modelling- or site-specific delivery systems), are further broadening the therapeutic scope. Key steps for future research should be the establishment of large-scale, multicenter randomized controlled trials; standardization and characterization of probiotic strains; precision interventions with probiotics tailored to patients potentially benefiting from such treatments (e.g., driven by nutrigenomic interactions) and harmonized regulatory guidelines to optimize safety vs beneficial clinical outcomes in both adults and children.

In summary, probiotics represent an evolving field that holds great promise for novel approaches to improve preventive medicine and disease management through personalized healthcare. Ongoing interdisciplinary research linking microbiology, immunology, genomics and biotechnology with clinical sciences will be critical to realizing the full therapeutic potential of probiotics as well as furthering evidence-based microbiome medicine.

Keywords: probiotics, gut microbiota, microbiome; mechanisms of action; clinical applications; health benefits or adverse effects on healthy subjects & patients (immunomodulation) ,synbiotics.